Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
7.8 USD -2.38% Intraday chart for Ocular Therapeutix, Inc. -2.38% +74.89%
Apr. 06 Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting CI
Mar. 25 Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
AQ
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
AQ
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
AQ
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
CI
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting
AQ
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
AQ
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours
MT
Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to S&P Pharmaceuticals Select Industry Index
CI
HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating
MT
TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating
MT
JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating
MT
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours
MT
Ocular Therapeutix: Q4 Earnings Snapshot
AQ
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M
MT
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
AQ
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.